Baylor Genome Center Standardizes on Roche NimbleGen Exome Capture Technology for Human Disease Studies
Because the majority of known diseasecausing mutations occur in the coding regions of the human genome (the exome), sequencing the exome allows researchers to focus on this highly important 1% of the genome and efficiently identify many of the genetic variants that are important for genetic diseases. The cost savings gained by exome sequencing in comparison to wholegenome sequencing allows researchers to investigate more biological samples and to do so more rapidly. It is also especially important for cancer studies, as the heterogeneous tumor tissues often require very deep sequencing, which is made economically possible by targeted enrichment.
"We have now been working with scientists from Roche NimbleGen for more than three years developing these optimized capture methods, said Dr. Richard Gibbs, director of HGSC and Wofford Cain Professor from Department of Molecular and Human Genetics at Baylor. "The different configurations of the SeqCap EZ Exome technology have superb performance in our hands, and will have profound influence on human disease studies"
Roche NimbleGen was the first company to offer a commercial solution for sequence capture and exome capture. Based on the success of the NimbleGen Sequence Capture 2.1M Exome Arrays which have enabled researchers worldwide to sequence thousands of exomes since late 2008, Roche NimbleGen launched SeqCap EZ Exome technology at the end of 2009. This new technology employs an insolution method that simplifies the workflow, provides highquality targeted capture/enrichment, and is scalable to easily facilitate research studies of any size.
In a recent study published in Genome Biology, scientists from the HGSC at Baylor and at Roche NimbleGen used SeqCap EZ Exome to demonstrate that as little as 3 Gb of raw sequence data is needed to discover >95% of expected heterozygous single base variants. In this study, SeqCap EZ Exome technology was coupled with multiple high throughput sequencing platforms for efficient resequencing of protein coding regions within the human genome.
"Roche NimbleGen is committed to providing the best exome capture technology for researchers worldwide," stated Dr. Andreas Görtz, VP of Marketing at Roche NimbleGen. "We believe studies like these carried out by leading research centers like the Baylor Human Genome Sequencing Center will provide insights on the missing heritability of many genetic diseases, hopefully leading to future breakthroughs in diagnostic and therapeutic tools."
For more information on Roche NimbleGen, visit www.nimblegen.com
Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in researchfocused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in invitro diagnostics, tissuebased cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Diese Pressemitteilungen könnten Sie auch interessieren
Weitere Informationen zum Thema "Forschung und Entwicklung":
Smart Cities knacken 2025 weltweit die 2-Billionen-Dollar-Marke
Das Marktforschungsunternehmen Frost & Sullivan prognostiziert für die Smart City goldene Zeiten. Im Jahr 2025 soll sie Geschäftsmöglichkeiten im Wert von zwei Billionen US-Dollar generieren. In der Hauptrolle der Smart Cities: Künstliche Intelligenz.Weiterlesen